ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 489,35
0,59%
Dow Jones
42 528,36
-0,42%
DAX
20 340,57
0,65%
Brent Oil
77,235
0,23%
Bitcoin
96 578,37
-0,33%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Silo Pharma Inc (SILO)

  7. Silo Pharma Inc (SILO) Actualités

SILO

Silo Pharma (SILO)

Silo Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SILO
DateHeureSourceTitreSymboleSociété
02/01/202517h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
02/01/202514h45GlobeNewswire Inc.Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic PainNASDAQ:SILOSilo Pharma Inc
18/12/202413h35GlobeNewswire Inc.Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and FibromyalgiaNASDAQ:SILOSilo Pharma Inc
16/12/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SILOSilo Pharma Inc
29/11/202414h05GlobeNewswire Inc.Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain ManagementNASDAQ:SILOSilo Pharma Inc
18/11/202414h40GlobeNewswire Inc.Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related DisordersNASDAQ:SILOSilo Pharma Inc
15/11/202423h21Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:SILOSilo Pharma Inc
12/11/202422h42Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SILOSilo Pharma Inc
08/11/202422h04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SILOSilo Pharma Inc
31/10/202413h35GlobeNewswire Inc.Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine ImplantNASDAQ:SILOSilo Pharma Inc
18/09/202422h19Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SILOSilo Pharma Inc
18/09/202422h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SILOSilo Pharma Inc
10/09/202412h35GlobeNewswire Inc.Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSDNASDAQ:SILOSilo Pharma Inc
04/09/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SILOSilo Pharma Inc
21/08/202423h20Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SILOSilo Pharma Inc
14/08/202420h30GlobeNewswire Inc.Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant TherapeuticNASDAQ:SILOSilo Pharma Inc
07/08/202414h13GlobeNewswire Inc.Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing PeptideNASDAQ:SILOSilo Pharma Inc
02/08/202419h16Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SILOSilo Pharma Inc
26/07/202422h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SILOSilo Pharma Inc
26/07/202414h20GlobeNewswire Inc.Silo Pharma to Present at H.C. Wainwright Annual Global Investment ConferenceNASDAQ:SILOSilo Pharma Inc
25/07/202422h30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SILOSilo Pharma Inc
22/07/202422h45GlobeNewswire Inc.Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
22/07/202412h06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SILOSilo Pharma Inc
19/07/202414h01GlobeNewswire Inc.Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
18/07/202414h25GlobeNewswire Inc.Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15NASDAQ:SILOSilo Pharma Inc
16/07/202412h30GlobeNewswire Inc.Silo Pharma Secures Exclusive Global License for Alzheimer's TherapeuticNASDAQ:SILOSilo Pharma Inc
08/07/202414h45GlobeNewswire Inc.Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety DisordersNASDAQ:SILOSilo Pharma Inc
26/06/202414h50GlobeNewswire Inc.Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and AnxietyNASDAQ:SILOSilo Pharma Inc
13/06/202423h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SILOSilo Pharma Inc
07/06/202414h18GlobeNewswire Inc.Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:SILO

Dernières Valeurs Consultées

NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
EU
ORA
Orange
NYSE
MRK
Merck
EU
ACA
Credit Agricole
FTSE
UKX
FTSE 100
EU
AI
Air Liquide
NASDAQ
MSFT
Microsoft
EU
LR
Legrand
COIN
ADAUSD
Cardano
USI
USTECH100
US Tech 100
NASDAQ
AAPL
Apple
EU
EN
Bouygues
EU
VK
Vallourec
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés